Previous Close | 15.95 |
1-Year Change | 4.04% |
6-Months Change | -23.17% |
3-Months Change | -21.51% |
Moving Avg (50d) | 18.708 |
Moving Avg (200d) | 20.821 |
ESG Rating | - |
Exchange | NASDAQ |
Market Cap. | 1.36B |
Beta (3-Years) | 1 |
Revenue Growth (ttm) | % |
Net Profit Margin (ttm) | -1856.64% |
Return On Assets (ttm) | -69.76% |
EPS (ttm) | -3.64 |
PE Ratio (ttm) | -4.38 |
Dividend Yield | % |
Asset Description: | Syndax Pharmaceuticals, Inc. |
Predicted Direction: | Buy |
Signal Strength: | Neutral |
Forecast Date: | 2024-10-14 00:00:00 |
Strong Buy | ||
Buy | ||
Neutral | ||
Sell | ||
Strong Sell |
2% | 5% | 7% | 10% | 15% | 20% |
15.631 | 15.152 | 14.833 | 14.355 | 13.557 | 12.76 |
Disclaimer - Please note that the use of AI to analyse contents may occasionally generate incorrect information.
Our cutting-edge algorithms employ macroeconomic data, fundamental and technical analysis indicators to accurately predict the optimal position for short-term trading
By harnessing these signals, we power our asset allocation tools, backtesting tool and portfolio management process, ensuring maximum returns for your investments.
Sector: | Health Care |
Industry: | Biotechnology |
Country: | United States |